Financials in USD. Standardized financial statements.
A compact view of how Orchestra BioMed Holdings, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue? | $33.48M | $2.64M | $2.76M | $3.53M | -$782,000 | $5.70M |
| Revenue Growth? | +1169.2% | -4.4% | -21.9% | +551.8% | -113.7% | 0.0% |
| Cost of Revenue? | $190,000 | $204,000 | $186,000 | $322,000 | $199,000 | $145,000 |
| Gross Profit? | $33.29M | $2.43M | $2.57M | $3.21M | -$981,000 | $5.56M |
| Gross Margin? | +99.4% | +92.3% | +93.3% | +90.9% | +125.4% | +97.5% |
| Operating Expenses? | $85.10M | $66.73M | $54.08M | $35.87M | $20.82M | $24.31M |
| Operating Income? | -$51.81M | -$64.30M | -$51.51M | -$32.66M | -$21.80M | -$18.75M |
| EBITDA? | -$51.23M | -$63.99M | -$51.22M | -$32.44M | -$21.62M | -$18.61M |
| Income Before Tax | -$52.70M | -$61.02M | -$49.12M | -$33.61M | -$23.01M | -$21.36M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$52.70M | -$61.02M | -$49.12M | -$33.61M | -$23.01M | -$21.36M |
| EPS? | $-1.38 | $-1.66 | $-1.48 | $-1.32 | $-0.02 | $-0.01 |
| Diluted EPS? | $-1.38 | $-1.66 | $-1.48 | $-1.32 | $-0.02 | $-0.01 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality